Ankier S, Kaye C
Br J Clin Pharmacol. 2012; 3(4):672-3.
PMID: 22216514
PMC: 1428895.
DOI: 10.1111/j.1365-2125.1976.tb04895.x.
Arnman K, Graffner C, Rikner L, Ryden L, Voog L
Eur J Clin Pharmacol. 1983; 24(2):199-203.
PMID: 6840167
DOI: 10.1007/BF00613817.
Chiariello M, Indolfi C, Cappelli Bigazzi M, Condorelli M
Eur J Clin Pharmacol. 1983; 24(1):35-9.
PMID: 6832199
DOI: 10.1007/BF00613924.
Keefe D, Kates R, Harrison D
Drugs. 1981; 22(5):363-400.
PMID: 6800757
DOI: 10.2165/00003495-198122050-00002.
Kumana C, Rambihar V, Willis K, Gupta R, Tanser P, Cairns J
Br J Clin Pharmacol. 1982; 14(4):529-37.
PMID: 6753888
PMC: 1427608.
DOI: 10.1111/j.1365-2125.1982.tb02024.x.
A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.
Kumana C, Rambihar V, Tanser P, Cairns J, Gupta R, Wildeman R
Br J Clin Pharmacol. 1982; 14(4):519-27.
PMID: 6753887
PMC: 1427600.
DOI: 10.1111/j.1365-2125.1982.tb02023.x.
Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.
Roberts C, Marshall A, Jordan S, Barritt D, Goodfellow R
Br J Clin Pharmacol. 1984; 18(5):725-32.
PMID: 6439233
PMC: 1463540.
DOI: 10.1111/j.1365-2125.1984.tb02535.x.
Prophylaxis of primary ventricular fibrillation in acute myocardial infarction. The case against lignocaine.
Kertes P, Hunt D
Br Heart J. 1984; 52(3):241-7.
PMID: 6380549
PMC: 481620.
DOI: 10.1136/hrt.52.3.241.
Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.
Postgrad Med J. 1984; 60(700):98-107.
PMID: 6369290
PMC: 2417724.
DOI: 10.1136/pgmj.60.700.98.
Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.
Brogden R, Todd P
Drugs. 1987; 34(2):151-87.
PMID: 3304965
DOI: 10.2165/00003495-198734020-00001.
Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.
Nattel S
Drugs. 1991; 41(5):672-701.
PMID: 1712704
DOI: 10.2165/00003495-199141050-00002.
Disopyramide in a case of recurrent ventricular fibrillation.
de Lanerolle T, EDMUNDS V, Wilcox A
Br Med J. 1976; 2(6039):795.
PMID: 974615
PMC: 1688674.
DOI: 10.1136/bmj.2.6039.795.
Disopyramide and warfarin interaction.
Haworth E, Burroughs A
Br Med J. 1977; 2(6091):866-7.
PMID: 922330
PMC: 1631678.
DOI: 10.1136/bmj.2.6091.866-a.
Prevention of ventricular arrhythmias after myocardial infarction.
Kidner P
J R Coll Physicians Lond. 1977; 11(4):352-62.
PMID: 886493
PMC: 5368753.
Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods.
Birkhead J, VAUGHAN WILLIAMS E
Br Heart J. 1977; 39(6):657-60.
PMID: 884018
PMC: 483295.
DOI: 10.1136/hrt.39.6.657.
Disopyramide in ventricular fibrillation.
de Lanerolle T
Br Med J. 1977; 1(6058):446.
PMID: 837158
PMC: 1604887.
DOI: 10.1136/bmj.1.6058.446.
Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
Bryson S, Whiting B, Lawrence J
Br J Clin Pharmacol. 1978; 6(5):409-19.
PMID: 728284
PMC: 1429565.
DOI: 10.1111/j.1365-2125.1978.tb04605.x.
Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.
Anderson J, Harrison D, Meffin P, Winkle R
Drugs. 1978; 15(4):271-309.
PMID: 648399
DOI: 10.2165/00003495-197815040-00003.
Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.
Hulting J, Jansson B
Eur J Clin Pharmacol. 1977; 11(2):91-9.
PMID: 320015
DOI: 10.1007/BF00562898.
Haemodynamic effects of disopyramide in patients after open-heart surgery.
Naqvi N, Thompson D, Morgan W, Williams B, Coltart D
Br Heart J. 1979; 42(5):587-94.
PMID: 316334
PMC: 482205.
DOI: 10.1136/hrt.42.5.587.
